<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Angela Sun, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Glucose-6-phosphatase deficiency (G6PD; MIM #232200), also known as von Gierke disease, is a glycogen storage disease (GSD). It was the first GSD to have the responsible enzyme defect identified and therefore is designated GSD I  (<a class="graphic graphic_table graphicRef54417" href="/d/graphic/54417.html" rel="external">table 1</a>). The defective enzymes involved in GSD I are mainly active in the liver and kidney. Patients present with manifestations related to hypoglycemia around three to four months of age. The diagnosis is confirmed by genetic testing. Treatment is focused on maintenance of physiologic glucose levels.</p><p>GSD I is reviewed in detail here. Other GSDs are reviewed separately. (See  <a class="medical medical_review" href="/d/html/2947.html" rel="external">"Liver glycogen synthase deficiency (glycogen storage disease 0)"</a> and  <a class="medical medical_review" href="/d/html/2905.html" rel="external">"Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)"</a> and  <a class="medical medical_review" href="/d/html/2916.html" rel="external">"Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)"</a> and  <a class="medical medical_review" href="/d/html/2906.html" rel="external">"Glycogen debrancher deficiency (glycogen storage disease III, Cori disease)"</a> and  <a class="medical medical_review" href="/d/html/2937.html" rel="external">"Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)"</a> and  <a class="medical medical_review" href="/d/html/2909.html" rel="external">"Myophosphorylase deficiency (glycogen storage disease V, McArdle disease)"</a> and  <a class="medical medical_review" href="/d/html/2944.html" rel="external">"Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)"</a> and  <a class="medical medical_review" href="/d/html/2907.html" rel="external">"Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)"</a>.)</p><p>A broader overview of GSD is also presented separately. (See  <a class="medical medical_review" href="/d/html/2941.html" rel="external">"Overview of inherited disorders of glucose and glycogen metabolism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of GSD I is 1/100,000 live births [<a href="#rid1">1</a>]. It is one of the most common types of GSDs.</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS AND CLASSIFICATION</span><span class="headingEndMark"> — </span>The hydrolysis and transport of glucose-6-phosphate (G6P) require a catalytic hydrolase and microsomal transporters for G6P, pyrophosphate, and glucose  (<a class="graphic graphic_figure graphicRef81164" href="/d/graphic/81164.html" rel="external">figure 1</a>). GSD I is caused by defects in the hydrolase (phosphatase) or translocase:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GSD Ia</strong> is due to a deficiency in the enzyme G6P hydrolase (glucose-6-phosphatase [G6Pase]) and comprises over 80 percent of cases of GSD I. G6Pase is expressed in the liver, intestine, and kidney.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GSD Ib</strong> (G6P transporter deficiency) is caused by a defect in the enzyme G6P translocase that is functionally associated with G6Pase. The translocase is ubiquitously expressed and functions as both a G6P transporter and a phosphate antiporter [<a href="#rid2">2</a>]. The enzyme also plays a role in neutrophil homeostasis and function [<a href="#rid3">3</a>].</p><p></p><p>Deficiency of either G6Pase or its transporter leads to progressive glycogen accumulation, mainly in the liver, and fasting hypoglycemia, which results in a number of secondary metabolic perturbations described below.</p><p class="headingAnchor" id="H4"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>GSD I is an autosomal-recessive disorder. The G6Pase gene, <em>G6PC</em>, is located on chromosome 17q21, while the glucose-6-phosphate translocase gene, solute carrier family 37 member 4 (<em>SLC37A4</em>)<em>,</em> is localized to chromosome 11q23.</p><p>Over 100 pathogenic variants have been identified in the <em>G6PC</em> gene [<a href="#rid4">4,5</a>]. Most are missense/nonsense mutations. Small deletions, insertions, and spice-site mutations have also been reported. Several common mutations exist in patients with GSD Ia:</p><p class="bulletIndent1"><span class="glyph">●</span>c.247C&gt;T (R83C) and c.1039C&gt;T (Q347X) are the most prevalent variants found in White patients [<a href="#rid6">6,7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>c.379_380dupTA (p.Tyr128Thrfs) and c.247C&gt;T (R83C) are the most prevalent variants in Hispanic patients [<a href="#rid6">6,7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>c.648G&gt;T (L216L), a splicing mutation, and c.248G&gt;A (R83H) are the most prevalent variants in the Chinese population [<a href="#rid4">4,6,7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>c.648G&gt;T (L216L) accounts for 91 percent of mutant alleles in Japan [<a href="#rid4">4,8</a>] and 75 percent of mutant alleles in Korea [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>c.247C&gt;T (R83C) accounts for 98 percent of variants in the Ashkenazi Jewish population [<a href="#rid9">9</a>].</p><p></p><p>Over 100 pathogenic variants in <em>SLC37A4</em> have been identified in patients with GSD Ib [<a href="#rid5">5</a>]. The majority are missense and nonsense mutations, but a significant number of deletions and splicing mutations are also seen.</p><p class="bulletIndent1"><span class="glyph">●</span>c.1015G&gt;T (G339C) and c.1042_1043delCT are the most common variants in White patients [<a href="#rid7">7,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>c.352T&gt;C (W118R) accounts for 50 percent of mutant alleles in the Japanese population [<a href="#rid7">7,11</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Affected patients most commonly present between three to six months of age with hepatomegaly, signs and symptoms of hypoglycemia, poor growth, and doll-like facies. In a report from the collaborative European study on GSD I, patients with GSD Ia and GSD Ib presented at a median age of six months (range 1 day to 12 years) and four months (range 1 day to 4 years), respectively [<a href="#rid12">12</a>]. The majority of both types presented before one year of age in this series.</p><p>In the European study, the following were the dominant presenting features [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Protruding abdomen – 83 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic derangement, including hypoglycemia, lactic acidosis, hypertriglyceridemia, and hyperuricemia – 71 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Growth failure (short stature, thin legs) – 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent bacterial infections – 3 percent in GSD Ia, 41 percent in GSD Ib</p><p class="bulletIndent1"><span class="glyph">●</span>Muscular hypotonia – 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed psychomotor development – 7 percent</p><p></p><p class="headingAnchor" id="H1052937"><span class="h2">Hypoglycemia</span><span class="headingEndMark"> — </span>Hypoglycemia is the hallmark finding in patients with GSD I. Unlike other GSDs, hypoglycemia in GSD I is characterized by hypoketosis due to inhibition of fatty acid oxidation by malonic acid [<a href="#rid13">13</a>]. Affected individuals have poor fasting tolerance, especially infants and young children, and may develop hypoglycemia within an hour or two after a meal. Symptoms of hypoglycemia include fatigue, irritability, nighttime waking to feed, and seizures. Patients often adapt to hypoglycemia and may be asymptomatic despite low blood glucose values.</p><p class="headingAnchor" id="H392172399"><span class="h2">Lactic acidosis</span><span class="headingEndMark"> — </span>Lactic acidosis is observed after fasting as G6Pase, in addition to its role in glycogen breakdown, is required for the final step of gluconeogenesis. Untreated patients may have serum lactate concentration between 5 to 10 mmol/L.</p><p class="headingAnchor" id="H600479553"><span class="h2">Hyperuricemia</span><span class="headingEndMark"> — </span>Many patients have hyperuricemia, which is secondary to decreased kidney clearance and increased production via degradation of adenine nucleotides [<a href="#rid14">14</a>]. Gout rarely develops before puberty [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H600479587"><span class="h2">Hyperlipidemia</span><span class="headingEndMark"> — </span>Marked hyperlipidemia, especially hypertriglyceridemia, occurs and can lead to xanthoma formation and pancreatitis. De novo triglyceride synthesis has been shown to increase over 10-fold in affected individuals, and the conversion of very-low-density lipoprotein (VLDL) to low-density lipoprotein (LDL) is delayed [<a href="#rid15">15</a>]. The relationship between hyperlipidemia and cardiovascular disease in patients with GSD I is unclear. Studies have shown both increased and normal carotid intima media thickness, and case series have yielded inconsistent observations regarding vascular dysfunction and markers of cardiovascular risk [<a href="#rid16">16-19</a>].</p><p class="headingAnchor" id="H600479663"><span class="h2">Hematologic abnormalities</span><span class="headingEndMark"> — </span>Anemia, while uncommon in treated patients, can be observed in both the pediatric and adult populations. It can result from chronic kidney disease, nutritional deficiencies, hemorrhage of hepatic adenomas, enterocolitis in type Ib patients, and other factors [<a href="#rid1">1</a>]. Platelet dysfunction can result in easy bruising and epistaxis. Patients with GSD Ib also have intermittent or chronic neutropenia and neutrophil dysfunction. In a report from a European registry of 57 GSD Ib patients, neutropenia occurred in 54 [<a href="#rid20">20</a>]. It was documented before one year of age in 64 percent of patients and first noted between six and nine years in 18 percent. Neutropenia was intermittent without a clear cyclical course in 45 patients and persistent in 5. (See  <a class="medical medical_review" href="/d/html/8373.html" rel="external">"Congenital neutropenia"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Gastrointestinal disease</span><span class="headingEndMark"> — </span>Inflammatory bowel disease (IBD) is common in GSD Ib [<a href="#rid21">21,22</a>]. Commonly reported symptoms include chronic abdominal pain, bloody diarrhea, perioral and perianal infections, and abscesses. IBD can occur in GSD Ia and may be underrecognized [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Endocrine disorders</span><span class="headingEndMark"> — </span>Short stature is common if patients are not appropriately managed. Puberty is often delayed, and menstrual cycles are frequently irregular [<a href="#rid24">24</a>]. Polycystic ovaries and menorrhagia have been observed. Fertility does not seem to be reduced, and successful pregnancies without the use of assistive reproductive measures have been reported [<a href="#rid1">1,24,25</a>]. An increased prevalence of thyroid autoimmunity and hypothyroidism has been reported in patients with GSD Ib [<a href="#rid26">26</a>]. Vitamin D levels are often low [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>Kidney disease results from glycogen accumulation in the kidney. Proteinuria, hematuria, nephrocalcinosis, and altered creatinine clearance typically follow a period of asymptomatic hyperfiltration. Stones result both from hypercalciuria and hyperuricosuria. The kidney appears enlarged, and histologic examination reveals focal segmental glomerulosclerosis and interstitial fibrosis [<a href="#rid14">14,28-30</a>]. (See  <a class="medical medical_review" href="/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a>.)</p><p>Hypertension  (<a class="graphic graphic_table graphicRef63856" href="/d/graphic/63856.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef52646" href="/d/graphic/52646.html" rel="external">table 3</a>) is common, and onset is typically in the second decade or later. A subset of patients develop progressive renal insufficiency and end-stage kidney disease [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Neurologic abnormalities</span><span class="headingEndMark"> — </span>Patients with GSD I are at risk for hypoglycemic seizures, which, if recurrent, can lead to neurodevelopmental impairment. Intelligence quotient (IQ) can be normal, but brain function and structure may be altered as a result of recurrent, severe hypoglycemia. In one study comparing brain function and morphology in patients with GSD I and age- and sex-matched controls, subjects with GSD I had increased prevalence of abnormal electroencephalograms (26 versus 3 percent), visual evoked potentials (38 versus 8 percent), somatosensory evoked potentials (23 versus 0 percent), brainstem auditory evoked potentials (16 versus 0 percent), and abnormal magnetic resonance imaging (MRI) studies (57 versus 0 percent) [<a href="#rid31">31</a>]. MRI abnormalities included dilation of the occipital horns and/or hyperintensity of subcortical white matter in the occipital or parietal lobes. Some of these abnormalities correlated with the frequency of hypoglycemic episodes requiring hospitalization, but the contribution of other factors, directly or indirectly related to GSD I, remains unclear. Intelligence quotient (IQ) was normal and similar between patients and controls (mean 97.2 and 100.1, respectively).</p><p class="headingAnchor" id="H1052957"><span class="h2">Hepatic adenomas</span><span class="headingEndMark"> — </span>Most adults develop liver adenomas in the second to third decade of life. The adenomas may lead to intrahepatic hemorrhage and undergo malignant transformation in approximately 10 percent of cases [<a href="#rid32">32</a>]. Enlargement of preexisting hepatic adenomas or appearance of new adenomas during pregnancy has been reported in GSD I patients [<a href="#rid24">24</a>]. Other focal hepatic lesions include hepatoblastoma, focal nodular hyperplasia, and focal fatty infiltration or sparing.</p><p class="headingAnchor" id="H646313187"><span class="h2">Decreased bone density</span><span class="headingEndMark"> — </span>Osteoporosis is seen in over half of adult patients with GSD Ia and Ib [<a href="#rid33">33</a>]. Decreased bone mineral density may be due to a chronic lactic acidosis, the effect of cortisol release (in response to hypoglycemia) on osteoblasts, and treatment of GSD itself, which involves dietary restriction of lactose and galactose that leads to vitamin D deficiency.</p><p class="headingAnchor" id="H2754622765"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>A small number of patients develop pulmonary hypertension, which can lead to progressive heart failure [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>GSD I should be suspected in patients with hypoglycemia, lactic acidemia, hypertriglyceridemia, hyperuricemia, and hepatomegaly, with or without neutropenia.</p><p>DNA testing is necessary to confirm the diagnosis of GSD Ia or Ib. Commercial sequencing of <em>G6PC</em> (G6Pase gene) and <em>SLC37A4 </em>(glucose-6-phosphate translocase gene) is widely available. Liver biopsies for histologic studies and enzyme analysis were performed historically but are rarely necessary nowadays. Liver histology demonstrates prominent storage of glycogen and considerable steatosis with minimal fibrosis.</p><p>A guideline for the diagnosis and management of GSD I is available from the American College of Medical Genetics and Genomics [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H455049781"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The main diagnoses to consider are the other hepatic forms of GSD that cause hypoglycemia. These are types 0, III, VI, and IX  (<a class="graphic graphic_table graphicRef54417" href="/d/graphic/54417.html" rel="external">table 1</a>). Patients with GSD type III may have extremely elevated aspartate transaminase (AST) and alanine transaminase (ALT) and milder hypoglycemia. In addition, uric acid and lactic acid are normal. Ketosis is much more pronounced in GSD types 0, III, VI, and IX compared with type I. GSD type 0 does not cause hepatomegaly. Ultimately, genetic testing is necessary to confirm the specific type of GSD.</p><p class="headingAnchor" id="H15"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Patients with GSD I should be managed by an experienced metabolic team including a biochemical geneticist, dietitian, nurse, and social worker. Other specialists may include a nephrologist, hepatologist, hematologist, and endocrinologist. A guideline for the diagnosis and management of GSD I is available from the American College of Medical Genetics and Genomics [<a href="#rid1">1</a>].</p><p>The goal of treatment is maintenance of physiologic glucose levels. Other clinical and biochemical parameters, such as somatic growth, lactic acidosis, and hypertriglyceridemia, improve in parallel with improved glucose control.</p><p>European guidelines for the management of GSD I recommend the following biochemical targets [<a href="#rid36">36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Preprandial blood glucose &gt;3.5 to 4.0 mmol/L (63 to 72 mg/dL)</p><p class="bulletIndent1"><span class="glyph">●</span>Urine lactate/creatinine ratio &lt;0.06 mmol/mmol</p><p class="bulletIndent1"><span class="glyph">●</span>Serum uric acid concentration in high normal range for age</p><p class="bulletIndent1"><span class="glyph">●</span>Venous blood bicarbonate &gt;20 mmol/L (20 mEq/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum triglyceride concentration &lt;6.0 mmol/L (531 mg/dL)</p><p class="bulletIndent1"><span class="glyph">●</span>Normal fecal alpha-1 antitrypsin concentration for GSD Ib</p><p class="bulletIndent1"><span class="glyph">●</span>Body mass index between 0.0 and + 2.0 standard deviations (<a class="calc calc_professional" href="/d/html/13412.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/d/html/13415.html" rel="external">calculator 2</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Prevention of hypoglycemia</span><span class="headingEndMark"> — </span>Infants should be fed at regular, age-appropriate intervals. In rare instances, they may require more frequent feeding. Early on, infants should not be allowed to sleep through the night. Some may require continuous feeds through a nasogastric or gastrostomy tube. An optimal infusion should provide 8 to 10 mg/kg/minute of glucose for an infant and 4 to 8 mg/kg/minute of glucose in an older child [<a href="#rid1">1</a>]. After one year of age, children should be given at least three daily meals with snacks in between.</p><p>Between meals, glucose concentrations are maintained with frequent oral administration of glucose, usually in the form of uncooked cornstarch, which is a glucose polymer that is broken down slowly. In many cases, a dose of cornstarch is needed during the night. Long-term treatment with uncooked cornstarch improves growth in GSD I patients [<a href="#rid37">37-39</a>]. Adverse effects of uncooked cornstarch include diarrhea, increased flatulence, and excess weight gain. Other commercial glucose polymer products are available and may allow longer fasting intervals between meals [<a href="#rid40">40</a>].</p><p>The dose of uncooked cornstarch is 1.6 g/kg every three to four hours for young children and 1.7 to 2.5 g/kg every four to six hours for older children, adolescents, and adults (1 tablespoon equals approximately 8.6 grams) [<a href="#rid1">1</a>]. Dosing is adjusted for the individual patient. Since infants do not digest cornstarch well due to lack of salivary amylase expression, it is recommended to begin cornstarch therapy after 6 to 12 months of age, when amylase activity increases. The need for cornstarch support decreases with age, and failure to adjust the dose in older patients can lead to excessive weight gain, worsening hepatomegaly, and relative hyperinsulinism [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H1052964"><span class="h2">Nutrition</span><span class="headingEndMark"> — </span>Working with a metabolic dietitian is essential in caring for patients with GSD I. Complex carbohydrates should comprise the majority of the diet (60 to 70 percent of total energy intake) [<a href="#rid1">1</a>]. Sugar, fruits, fruit juices, high-fructose corn syrup, and <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> should be avoided. Lactose, galactose, fructose, and sucrose should be limited since they also depend on G6Pase for metabolism. Infants should be fed a soy-based formula. Unlike other GSDs, a high-protein diet is not useful to maintain glucose in GSD I, since gluconeogenesis also depends upon hydrolysis of glucose-6-phosphate (G6P). Essential vitamins and minerals, especially calcium and vitamin D, should be provided through the diet or by supplementation if needed.</p><p class="headingAnchor" id="H600480232"><span class="h2">Treatment of lactic acidosis</span><span class="headingEndMark"> — </span>Lactic acidosis, if persistent, can be treated with oral citrate or bicarbonate administration, which also alkalinizes the urine and decreases the risk of urolithiasis and nephrocalcinosis.</p><p class="headingAnchor" id="H19"><span class="h2">Treatment of hyperuricemia</span><span class="headingEndMark"> — </span>There is no consensus as to when to treat hyperuricemia with medications. <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">Allopurinol</a> lowers uric acid levels and can be used in patients with persistently elevated uric acid or with recurrent attacks of gout. <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> may be used during acute attacks. Use of medium-chain triglyceride oil was shown in a small study to improve uric acid levels and reduce carbohydrate requirements [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H600480175"><span class="h2">Treatment of hyperlipidemia</span><span class="headingEndMark"> — </span>Lipid-lowering agents such as 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors and fibrate may be used. Dietary interventions (eg, administration of medium-chain triglycerides) may be effective at reducing triglyceride and lactic acid levels by improving fatty acid oxidation and reducing glycolysis but require additional evaluation [<a href="#rid43">43</a>]. However, hyperlipidemia in patients with GSD I only responds partially to drug therapy and/or dietary measures. It resolves completely after liver transplantation [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management"</a> and  <a class="medical medical_review" href="/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.)</p><p>Fish oil does not persistently lower serum triglyceride and cholesterol concentration and may increase atherogenesis by increasing lipoprotein oxidation [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H600480298"><span class="h2">Neutropenia</span><span class="headingEndMark"> — </span>Patients with GSD Ib and neutropenia should be treated with granulocyte colony-stimulating factor (G-CSF) [<a href="#rid1">1,46</a>]. Treatment with G-CSF increases neutrophil count, decreases the frequency and severity of infections, and improves inflammatory bowel symptoms [<a href="#rid46">46,47</a>]. Splenomegaly is the most serious complication of G-CSF.</p><p>The antidiabetic drug <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> was shown to improve neutropenia and inflammatory bowel disease by reducing plasma levels of 1,5-anhydroglucitol-6-phosphate, a structural analog of G6P that accumulates in neutrophils of patients with GSD Ib [<a href="#rid48">48,49</a>]. Clinical trials are underway (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04986735&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPBj9Yoj0B1ISD9WSPN1sKV%2BUBpVKLdR180sVgdH2rxSQ%3D%3D&amp;TOPIC_ID=2946" target="_blank">NCT04986735</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04930627&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPRz%2FgPxHVOri1PRZlUar6qMdc%2BJuG9za47htfgxFFk4A%3D%3D&amp;TOPIC_ID=2946" target="_blank">NCT04930627</a>).</p><p>Reactive oxygen species are thought to play a role in activating apoptosis in neutrophils of patients with GSD Ib, suggesting that antioxidant therapy may be beneficial. Supplementation with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> has been shown to increase mean neutrophil count, decrease the frequency and severity of infections, and, in some cases, allow for dose reduction of G-CSF [<a href="#rid50">50,51</a>].These findings show promise as an adjunct or alternative treatment but should be replicated in larger, placebo-controlled trials before vitamin E therapy can be routinely suggested for the treatment of patients with GSD Ib.</p><p class="headingAnchor" id="H646313208"><span class="h2">Anemia</span><span class="headingEndMark"> — </span>Treatment of anemia may include iron supplementation and erythropoietin, depending upon the severity [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Inflammatory bowel disease</span><span class="headingEndMark"> — </span>IBD is treated with the usual approach. Patients have also responded to G-CSF and <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, which is used to treat neutropenia (see <a class="local">'Neutropenia'</a> above). Successful treatment of refractory GSD-related IBD with <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> has been reported [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents"</a> and <a class="local">'Neutropenia'</a> above.)</p><p class="headingAnchor" id="H24"><span class="h2">Short stature</span><span class="headingEndMark"> — </span>Growth hormone does not affect the final height and should not be used, because it can lead to the development of or an increase in the size or number of liver adenomas [<a href="#rid1">1,36</a>]. Good metabolic control leads to improved height and weight.</p><p class="headingAnchor" id="H646313228"><span class="h2">Osteoporosis</span><span class="headingEndMark"> — </span>Dual-energy x-ray absorptiometry (DXA) scans and vitamin D 25-OH levels should be checked regularly to monitor bone health. Calcium and vitamin D supplementation are necessary given the restricted nature of the diet [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1892107488"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>A kidney ultrasound should be obtained annually to assess for kidney enlargement and nephrolithiasis. Blood urea nitrogen, creatinine, urinalysis, quantitation of microalbumin, and other kidney function studies should be checked at routine intervals, typically annually in children and every six months in adults [<a href="#rid1">1</a>]. Alkalinization of the urine with oral citrate decreases the risk of stone formation. <a class="drug drug_general" data-topicid="10225" href="/d/drug information/10225.html" rel="external">Potassium citrate</a> is preferred over bicarbonate because hypocitraturia appears to worsen with age in GSD Ia [<a href="#rid53">53</a>].</p><p>An angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) should be started in patients with persistent microalbuminuria to decrease deterioration of kidney function [<a href="#rid1">1,36,54</a>]. Hypertension that persists despite ACE inhibition should also be treated. Kidney transplant, often combined with liver transplant, can be performed in patients with end-stage kidney disease.</p><p class="headingAnchor" id="H455049813"><span class="h2">Hepatocellular carcinoma</span><span class="headingEndMark"> — </span>Hepatocellular carcinoma (HCC) is a known late complication GSD I [<a href="#rid55">55</a>]. Adenoma to HCC transformation may occur in persons with good metabolic control [<a href="#rid56">56</a>]. A liver ultrasound should be performed every 12 to 24 months in children &lt;18 years of age to screen for HCC. Computed tomography (CT) or magnetic resonance imaging (MRI) with contrast is recommended every 6 to 12 months in older patients [<a href="#rid1">1</a>]. Oral contraceptive pills are contraindicated in women with GSD I since estrogen increases the risk for hepatic adenomas. However, progestin-only contraceptives are an option [<a href="#rid1">1,24</a>]. During pregnancy, adenomas must be monitored due to the risk for enlargement and rupture. (See <a class="local">'Hepatic adenomas'</a> above.)</p><p class="headingAnchor" id="H1226450745"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>An echocardiogram should be performed starting at 10 years of age to screen for pulmonary hypertension [<a href="#rid1">1,36</a>]. This study should be repeated every three years or sooner if clinically indicated.</p><p class="headingAnchor" id="H26"><span class="h2">Liver transplantation</span><span class="headingEndMark"> — </span>Liver transplantation is indicated in GSD I patients with poor metabolic control, worsening adenomas, HCC, and/or liver or kidney failure [<a href="#rid1">1,57</a>]. Transplantation results in resolution of hypoglycemia and secondary metabolic disturbances including lactic acidosis, hypertriglyceridemia, and hyperuricemia [<a href="#rid44">44,57</a>]. Patients can eat a normal diet after liver transplantation. Growth deficiency and neutropenia often persist in GSD Ib after transplantation [<a href="#rid58">58</a>].</p><p>Some patients with GSD Ia develop kidney failure after liver transplant. This may be due to natural disease progression or an adverse effect of immunosuppressive medications. Combined liver and kidney transplant can be done [<a href="#rid59">59-62</a>].</p><p class="headingAnchor" id="H1108005130"><span class="h2">Other (or future) therapies</span><span class="headingEndMark"> — </span>Clinical trials for gene therapy for GSD Ia are underway (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03517085&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPQhnee0UzwZv2mNDOW%2FZgP9c3s%2BAR6Kna9qYkcxbwjrQ%3D%3D&amp;TOPIC_ID=2946" target="_blank">NCT03517085</a>). Gene therapy in mouse models of GSD Ib appears effective in restoring G6P translocase activity [<a href="#rid63">63</a>], and human trials may follow. A clinical trial investigating the use of <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> to treat neutropenia in GSD Ib patients is ongoing (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04930627&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPRz%2FgPxHVOri1PRZlUar6qMdc%2BJuG9za47htfgxFFk4A%3D%3D&amp;TOPIC_ID=2946" target="_blank">NCT04930627</a>).</p><p class="headingAnchor" id="H161035966"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Complications due to GSD I persist in adults. In one report, long-term outcomes were evaluated in 37 patients with GSD Ia and five patients with GSD Ib who were ≥18 years of age [<a href="#rid64">64</a>]. The following outcomes were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly – 100 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Short stature – 90 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperuricemia – 89 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia – 81 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hypercholesterolemia – 76 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Increased serum triglycerides – 100 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic adenomas – 75 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Proteinuria or microalbuminuria – 67 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Renal calcifications – 65 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Osteopenia or fractures – 27 percent</p><p></p><p class="headingAnchor" id="H1484968176"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118189.html" rel="external">"Society guideline links: Glycogen storage disease types I and II"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Glucose-6-phosphatase deficiency (G6PD; glycogen storage disease type I [GSD I]), also known as von Gierke disease, is an autosomal-recessive disorder caused by a deficiency of glucose-6-phosphate (G6P) hydrolase (type Ia) or G6P translocase (type Ib)  (<a class="graphic graphic_figure graphicRef81164" href="/d/graphic/81164.html" rel="external">figure 1</a>). (See <a class="local">'Pathogenesis and classification'</a> above and <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Affected patients typically present in early infancy with failure to thrive, hepatomegaly, hypoglycemia, seizures, and lactic acidosis. Additional manifestations include kidney disease, hyperuricemia, hypertriglyceridemia, and, in patients with type Ib GSD, recurrent infections due to neutropenia. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of GSD I is confirmed by genetic testing. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The goal of treatment is to maintain physiologic glucose levels. Other biochemical parameters, such as lactic acidosis and hypertriglyceridemia, improve in parallel with improved glucose control. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucose concentrations are maintained with regular meals, snacks, and administration of uncooked cornstarch. (See <a class="local">'Prevention of hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional treatment measures may be necessary for hyperuricemia, hyperlipidemia, microalbuminuria, hypertension, neutropenia, and inflammatory bowel disease (IBD). (See <a class="local">'Management'</a> above.)</p><p></p><p class="headingAnchor" id="H1052820"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William J Craigen, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kishnani PS, Austin SL, Abdenur JE, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med 2014; 16:e1.</a></li><li><a class="nounderline abstract_t">Chen SY, Pan CJ, Nandigama K, et al. The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic. FASEB J 2008; 22:2206.</a></li><li><a class="nounderline abstract_t">Chou JY, Jun HS, Mansfield BC. Neutropenia in type Ib glycogen storage disease. Curr Opin Hematol 2010; 17:36.</a></li><li><a class="nounderline abstract_t">Chou JY, Mansfield BC. Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum Mutat 2008; 29:921.</a></li><li class="breakAll">The Human Gene Mutation Database at http://www.hgmd.cf.ac.uk/ac/index.php (Accessed on December 03, 2019).</li><li><a class="nounderline abstract_t">Lei KJ, Chen YT, Chen H, et al. Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus. Am J Hum Genet 1995; 57:766.</a></li><li><a class="nounderline abstract_t">Matern D, Seydewitz HH, Bali D, et al. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr 2002; 161 Suppl 1:S10.</a></li><li><a class="nounderline abstract_t">Akanuma J, Nishigaki T, Fujii K, et al. Glycogen storage disease type Ia: molecular diagnosis of 51 Japanese patients and characterization of splicing mutations by analysis of ectopically transcribed mRNA from lymphoblastoid cells. Am J Med Genet 2000; 91:107.</a></li><li><a class="nounderline abstract_t">Ekstein J, Rubin BY, Anderson SL, et al. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet A 2004; 129A:162.</a></li><li><a class="nounderline abstract_t">Veiga-da-Cunha M, Gerin I, Chen YT, et al. The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a. Eur J Hum Genet 1999; 7:717.</a></li><li><a class="nounderline abstract_t">Kure S, Suzuki Y, Matsubara Y, et al. Molecular analysis of glycogen storage disease type Ib: identification of a prevalent mutation among Japanese patients and assignment of a putative glucose-6-phosphate translocase gene to chromosome 11. Biochem Biophys Res Commun 1998; 248:426.</a></li><li><a class="nounderline abstract_t">Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161 Suppl 1:S20.</a></li><li><a class="nounderline abstract_t">Binkiewicz A, Senior B. Decreased ketogenesis in von Gierke's disease (type I glycogenosis). J Pediatr 1973; 83:973.</a></li><li class="breakAll">Chen YT, Kishnani PS, Koeberl D. Glycogen Storage Diseases. The Online Metabolic and Molecular Bases of Inherited Disease. http://ommbid.mhmedical.com/ommbid-index.aspx (Accessed on December 03, 2019).</li><li><a class="nounderline abstract_t">Bandsma RH, Prinsen BH, van Der Velden Mde S, et al. Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res 2008; 63:702.</a></li><li><a class="nounderline abstract_t">Bernier AV, Correia CE, Haller MJ, et al. Vascular dysfunction in glycogen storage disease type I. J Pediatr 2009; 154:588.</a></li><li><a class="nounderline abstract_t">Ubels FL, Rake JP, Slaets JP, et al. Is glycogen storage disease 1a associated with atherosclerosis? Eur J Pediatr 2002; 161 Suppl 1:S62.</a></li><li><a class="nounderline abstract_t">Carvalho PM, Silva NJ, Dias PG, et al. Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases. J Diabetes Metab Disord 2013; 12:25.</a></li><li><a class="nounderline abstract_t">Schmitt J, Wurm M, Schwab KO, et al. Glycogen storage disease type I patients with hyperlipidemia have no signs of early vascular dysfunction and premature atherosclerosis. Nutr Metab Cardiovasc Dis 2021; 31:3384.</a></li><li><a class="nounderline abstract_t">Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr 2000; 137:187.</a></li><li><a class="nounderline abstract_t">Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 2002; 161 Suppl 1:S88.</a></li><li><a class="nounderline abstract_t">Wicker C, Roda C, Perry A, et al. Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort. Mol Genet Metab Rep 2020; 23:100581.</a></li><li><a class="nounderline abstract_t">Lawrence NT, Chengsupanimit T, Brown LM, et al. Inflammatory Bowel Disease in Glycogen Storage Disease Type Ia. J Pediatr Gastroenterol Nutr 2017; 64:e52.</a></li><li><a class="nounderline abstract_t">Sechi A, Deroma L, Lapolla A, et al. Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study. J Inherit Metab Dis 2013; 36:83.</a></li><li><a class="nounderline abstract_t">Ryan IP, Havel RJ, Laros RK Jr. Three consecutive pregnancies in a patient with glycogen storage disease type IA (von Gierke's disease). Am J Obstet Gynecol 1994; 170:1687.</a></li><li><a class="nounderline abstract_t">Melis D, Pivonello R, Parenti G, et al. Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I. J Pediatr 2007; 150:300.</a></li><li><a class="nounderline abstract_t">Banugaria SG, Austin SL, Boney A, et al. Hypovitaminosis D in glycogen storage disease type I. Mol Genet Metab 2010; 99:434.</a></li><li><a class="nounderline abstract_t">Chen YT, Coleman RA, Scheinman JI, et al. Renal disease in type I glycogen storage disease. N Engl J Med 1988; 318:7.</a></li><li><a class="nounderline abstract_t">Chen YT. Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment. Pediatr Nephrol 1991; 5:71.</a></li><li><a class="nounderline abstract_t">Reitsma-Bierens WC. Renal complications in glycogen storage disease type I. Eur J Pediatr 1993; 152 Suppl 1:S60.</a></li><li><a class="nounderline abstract_t">Melis D, Parenti G, Della Casa R, et al. Brain damage in glycogen storage disease type I. J Pediatr 2004; 144:637.</a></li><li><a class="nounderline abstract_t">Lee PJ. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 2002; 161 Suppl 1:S46.</a></li><li><a class="nounderline abstract_t">Minarich LA, Kirpich A, Fiske LM, Weinstein DA. Bone mineral density in glycogen storage disease type Ia and Ib. Genet Med 2012.</a></li><li><a class="nounderline abstract_t">Furukawa N, Kinugasa A, Inoue F, et al. Type I glycogen storage disease with vasoconstrictive pulmonary hypertension. J Inherit Metab Dis 1990; 13:102.</a></li><li><a class="nounderline abstract_t">Humbert M, Labrune P, Simonneau G. Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr 2002; 161 Suppl 1:S93.</a></li><li><a class="nounderline abstract_t">Rake JP, Visser G, Labrune P, et al. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161 Suppl 1:S112.</a></li><li><a class="nounderline abstract_t">Chen YT, Cornblath M, Sidbury JB. Cornstarch therapy in type I glycogen-storage disease. N Engl J Med 1984; 310:171.</a></li><li><a class="nounderline abstract_t">Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr 2002; 161 Suppl 1:S35.</a></li><li><a class="nounderline abstract_t">Chen YT, Bazzarre CH, Lee MM, et al. Type I glycogen storage disease: nine years of management with cornstarch. Eur J Pediatr 1993; 152 Suppl 1:S56.</a></li><li><a class="nounderline abstract_t">Correia CE, Bhattacharya K, Lee PJ, et al. Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Am J Clin Nutr 2008; 88:1272.</a></li><li><a class="nounderline abstract_t">Dahlberg KR, Ferrecchia IA, Dambska-Williams M, et al. Cornstarch requirements of the adult glycogen storage disease Ia population: A retrospective review. J Inherit Metab Dis 2020; 43:269.</a></li><li><a class="nounderline abstract_t">Das AM, Lücke T, Meyer U, et al. Glycogen storage disease type 1: impact of medium-chain triglycerides on metabolic control and growth. Ann Nutr Metab 2010; 56:225.</a></li><li><a class="nounderline abstract_t">Nagasaka H, Hirano K, Ohtake A, et al. Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk. Eur J Pediatr 2007; 166:1009.</a></li><li><a class="nounderline abstract_t">Iyer SG, Chen CL, Wang CC, et al. Long-term results of living donor liver transplantation for glycogen storage disorders in children. Liver Transpl 2007; 13:848.</a></li><li><a class="nounderline abstract_t">Bandsma RH, Rake JP, Visser G, et al. Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a. J Pediatr 2002; 140:256.</a></li><li><a class="nounderline abstract_t">Visser G, Rake JP, Labrune P, et al. Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 2002; 161 Suppl 1:S120.</a></li><li><a class="nounderline abstract_t">Dale DC, Bolyard AA, Marrero T, et al. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. Curr Opin Hematol 2019; 26:16.</a></li><li><a class="nounderline abstract_t">Wortmann SB, Van Hove JLK, Derks TGJ, et al. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood 2020; 136:1033.</a></li><li><a class="nounderline abstract_t">Grünert SC, Elling R, Maag B, et al. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib. Orphanet J Rare Dis 2020; 15:218.</a></li><li><a class="nounderline abstract_t">Melis D, Della Casa R, Parini R, et al. Vitamin E supplementation improves neutropenia and reduces the frequency of infections in patients with glycogen storage disease type 1b. Eur J Pediatr 2009; 168:1069.</a></li><li><a class="nounderline abstract_t">Melis D, Minopoli G, Balivo F, et al. Vitamin E Improves Clinical Outcome of Patients Affected by Glycogen Storage Disease Type Ib. JIMD Rep 2016; 25:39.</a></li><li><a class="nounderline abstract_t">Davis MK, Rufo PA, Polyak SF, Weinstein DA. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J Inherit Metab Dis 2008; 31 Suppl 3:505.</a></li><li><a class="nounderline abstract_t">Weinstein DA, Somers MJ, Wolfsdorf JI. Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr 2001; 138:378.</a></li><li><a class="nounderline abstract_t">Melis D, Parenti G, Gatti R, et al. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study. Clin Endocrinol (Oxf) 2005; 63:19.</a></li><li><a class="nounderline abstract_t">Franco LM, Krishnamurthy V, Bali D, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 2005; 28:153.</a></li><li><a class="nounderline abstract_t">Kaiser N, Gautschi M, Bosanska L, et al. Glycemic control and complications in glycogen storage disease type I: Results from the Swiss registry. Mol Genet Metab 2019; 126:355.</a></li><li><a class="nounderline abstract_t">Boers SJ, Visser G, Smit PG, Fuchs SA. Liver transplantation in glycogen storage disease type I. Orphanet J Rare Dis 2014; 9:47.</a></li><li><a class="nounderline abstract_t">Shimizu S, Sakamoto S, Horikawa R, et al. Longterm Outcomes of Living Donor Liver Transplantation for Glycogen Storage Disease Type 1b. Liver Transpl 2020; 26:57.</a></li><li><a class="nounderline abstract_t">Demirci G, Becker T, Nyibata M, et al. Results of combined and sequential liver-kidney transplantation. Liver Transpl 2003; 9:1067.</a></li><li><a class="nounderline abstract_t">Belingheri M, Ghio L, Sala A, et al. Combined liver-kidney transplantation in glycogen storage disease Ia: a case beyond the guidelines. Liver Transpl 2007; 13:762.</a></li><li><a class="nounderline abstract_t">Panaro F, Andorno E, Basile G, et al. Simultaneous liver-kidney transplantation for glycogen storage disease type IA (von Gierke's disease). Transplant Proc 2004; 36:1483.</a></li><li><a class="nounderline abstract_t">Marega A, Fregonese C, Tulissi P, et al. Preemptive liver-kidney transplantation in von Gierke disease: a case report. Transplant Proc 2011; 43:1196.</a></li><li><a class="nounderline abstract_t">Kwon JH, Lee YM, Cho JH, et al. Liver-directed gene therapy for murine glycogen storage disease type Ib. Hum Mol Genet 2017; 26:4395.</a></li><li><a class="nounderline abstract_t">Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994; 120:218.</a></li></ol></div><div id="topicVersionRevision">Topic 2946 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25356975" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337460" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19741523" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neutropenia in type Ib glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18449899" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18449899" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573034" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373566" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Glycogen storage disease type I: diagnosis and phenotype/genotype correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10748407" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Glycogen storage disease type Ia: molecular diagnosis of 51 Japanese patients and characterization of splicing mutations by analysis of ectopically transcribed mRNA from lymphoblastoid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316959" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482962" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9675154" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Molecular analysis of glycogen storage disease type Ib: identification of a prevalent mutation among Japanese patients and assignment of a putative glucose-6-phosphate translocase gene to chromosome 11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373567" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4518932" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Decreased ketogenesis in von Gierke's disease (type I glycogenosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4518932" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Decreased ketogenesis in von Gierke's disease (type I glycogenosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520334" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19101686" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Vascular dysfunction in glycogen storage disease type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373574" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Is glycogen storage disease 1a associated with atherosclerosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23738826" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34627694" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Glycogen storage disease type I patients with hyperlipidemia have no signs of early vascular dysfunction and premature atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931410" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373579" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of glycogen storage disease 1b and Crohn disease: results of a North American survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32300528" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25304890" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inflammatory Bowel Disease in Glycogen Storage Disease Type Ia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22562700" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203427" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Three consecutive pregnancies in a patient with glycogen storage disease type IA (von Gierke's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307551" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20060350" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hypovitaminosis D in glycogen storage disease type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3422104" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Renal disease in type I glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2025544" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319728" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Renal complications in glycogen storage disease type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127000" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Brain damage in glycogen storage disease type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373570" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Glycogen storage disease type I: pathophysiology of liver adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22481133" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bone mineral density in glycogen storage disease type Ia and Ib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2109144" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Type I glycogen storage disease with vasoconstrictive pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373580" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Severe pulmonary arterial hypertension in type 1 glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373584" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6581385" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cornstarch therapy in type I glycogen-storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373568" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319727" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Type I glycogen storage disease: nine years of management with cornstarch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18996862" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31415093" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cornstarch requirements of the adult glycogen storage disease Ia population: A retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20357432" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Glycogen storage disease type 1: impact of medium-chain triglycerides on metabolic control and growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17206455" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17539004" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term results of living donor liver transplantation for glycogen storage disorders in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865283" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373585" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30451720" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32294159" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32838757" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066956" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vitamin E supplementation improves neutropenia and reduces the frequency of infections in patients with glycogen storage disease type 1b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26122627" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vitamin E Improves Clinical Outcome of Patients Affected by Glycogen Storage Disease Type Ib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172743" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241046" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Decreased urinary citrate excretion in type 1a glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963056" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15877204" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hepatocellular carcinoma in glycogen storage disease type Ia: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30846352" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Glycemic control and complications in glycogen storage disease type I: Results from the Swiss registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24716823" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Liver transplantation in glycogen storage disease type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31587472" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Longterm Outcomes of Living Donor Liver Transplantation for Glycogen Storage Disease Type 1b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14526402" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Results of combined and sequential liver-kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457869" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Combined liver-kidney transplantation in glycogen storage disease Ia: a case beyond the guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15251364" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Simultaneous liver-kidney transplantation for glycogen storage disease type IA (von Gierke's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21620087" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Preemptive liver-kidney transplantation in von Gierke disease: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973635" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Liver-directed gene therapy for murine glycogen storage disease type Ib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8273986" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Glycogen storage disease in adults.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
